Financhill is a comprehensive financial analysis platform that provides stock analysis, market data, investment tools, and educational resources to help investors make informed decisions.

How do I get started with Financhill?

You can start by creating a free account, exploring our stock analysis tools, setting up a watchlist, or trying our 7-day trial for full access to all premium features.

What features does Financhill offer?

Financhill offers stock analysis, technical charts, fundamental data, earnings information, dividend tracking, portfolio management, market screening tools, and educational resources.

What are 10K annual reports?

10K reports are comprehensive annual reports filed by public companies with the SEC, containing detailed financial statements, business operations, risk factors, and management discussion.

How often are annual reports updated?

Annual reports are typically filed once per year, usually within 60-90 days after the company's fiscal year end. We update our database as soon as new reports become available.

How do I analyze CORT stock?

Use our comprehensive analysis tools including technical charts, fundamental metrics, earnings data, and Stock Score to evaluate CORT investment potential.

What is CORT stock price today?

Get real-time CORT stock price, historical data, and price charts on Financhill. Track CORT performance with our advanced analysis tools.

Is CORT a good investment?

Evaluate CORT investment potential using our Stock Score, fundamental analysis, technical indicators, and earnings data. Consider your risk tolerance and investment goals.

How to buy CORT stock?

To buy CORT stock, open a brokerage account, research the company using our analysis tools, and place your order through your broker. Always do your own research before investing.

What is the market cap of CORT?

View detailed market capitalization data and company valuation metrics for CORT on our comprehensive analysis page.

What is the P/E ratio of CORT?

Use our fundamental analysis tools to view CORT P/E ratio and compare valuation metrics with industry peers.

What are CORT earnings?

View CORT earnings data, quarterly results, revenue growth, and profit margins on our comprehensive earnings analysis page. Track earnings trends and analyst estimates.

Back

Corcept Therapeutics, Inc. 10K Form

Buy

CORT
Corcept Therapeutics, Inc.

Last Price:

$84.71

Seasonality Move:

6.49%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

2024-05-01	10Q	CORT/Corcept Therapeutics, Inc. Quarterly
2023-11-01	10Q	CORT/Corcept Therapeutics, Inc. Quarterly
2023-08-02	10Q	CORT/Corcept Therapeutics, Inc. Quarterly
2023-05-03	10Q	CORT/Corcept Therapeutics, Inc. Quarterly
2022-11-03	10Q	CORT/Corcept Therapeutics, Inc. Quarterly
2022-08-04	10Q	CORT/Corcept Therapeutics, Inc. Quarterly

Receive CORT News And Ratings

See the #1 stock for the next 7 days that we like better than CORT

CORT Financial Statistics

Sales & Book Value

Annual Sales:	$675M
Cash Flow:	$54.5M
Price / Cash Flow:	62.26
Annual Sales:	$6.01
Price / Book:	14.09

Profitability

EPS (TTM):	0.87520
Net Income (TTM):	$104.6M
Gross Margin:	$664.2M
Return on Equity:	16%
Return on Assets:	12.77%

Corcept Therapeutics, Inc. Earnings Forecast

Key Corcept Therapeutics, Inc. Financial Ratios

The Gross Profit Margin over the past 20 years for CORT is 98.39%.
The Selling, General & Administrative Expenses for CORT have been equal to 41.53% of Gross Profit Margin.
The Research & Development expenses have been 36.57% of Revenue.
The Interest Expense is 0.00% of Operating Income.
The Net Earning history of CORT is 20.70% of Total Revenues.
Per Share Earnings over the last 24 years have been positive in 13 years.

Corcept Therapeutics, Inc. Stock Price Chart

Industry, Sector and Symbol

Stock Exchange:	NASDAQ
Industry:	Pharmaceuticals
Sector:	Health Care
Current Symbol:	CORT
CUSIP:	218352
Website:	corcept.com

Debt

Debt-to-Equity Ratio:	0.01
Current Ratio:	3.14
Quick Ratio:	2.85

Price-to-Earnings

Trailing P/E Ratio:	68.76
Forward P/E Ratio:	68.72

CORT Technical Analysis vs Fundamental Analysis

Buy

Corcept Therapeutics, Inc. (CORT) is a Buy

Is Corcept Therapeutics, Inc. a Buy or a Sell?

Corcept Therapeutics, Inc. stock is rated a Buy

The current Corcept Therapeutics, Inc. [CORT] share price is $84.66. The Score for CORT is 62, which is 24% above its historic median score of 50, and infers lower risk than normal.